Benchmark Reiterates Buy Rating on Prenetics Global Limited (PRE)
Benchmark reaffirms its buy rating on Prenetics Global with a $30 price target, a 46.48% upside from the current price.
Key Points
- Benchmark, on June 16, 2026, reiterated its buy rating on Prenetics Global Limited with a $30 price target.
- Benchmark's $30 price target implies 46.48% upside from Prenetics Global Limited's ($PRE) current $20.48 share price.
- Shares of NasdaqGM:PRE traded at $20.75, with a market cap of $348.7 million, forward P/E is not meaningful as the company isn't profitable.
- Insiders including CFO Lo Hoi Chun acquired shares recently, and other analysts like Lake Street also initiated buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Benchmark has reiterated its buy rating for Prenetics Global Limited (NasdaqGM: PRE) on June 16, 2026. Analyst Bill Sutherland set a price target of $30, suggesting confidence in the company's prospects.
Other Institutional Activity in Prenetics Global
Several other institutional investors have been active in Prenetics Global. Goldman Sachs Group Inc added 151,338 shares, bringing its total to 193,583 shares valued at about $3.74 million. Millennium Management LLC increased its holdings by 141,168 shares to a total of 192,600 shares, worth approximately $3.72 million. Wells Fargo & Company/MN made a significant move by adding 81,806 shares, ending with 84,806 shares valued at $1.64 million.
Prenetics Global Limited Stock Down 20.5%
Shares of Prenetics Global (NasdaqGM: PRE) traded at $20.75. The company has a market cap of $348.7 million. Its forward P/E ratio isn't meaningful since the company is not currently profitable. Prenetics has a beta of 0.239, indicating low volatility compared to the market. The stock's 52-week range is between $7.05 and $23.63, with a 50-day moving average of $18.21 and a 200-day moving average of $16.34. The company maintains a strong liquidity position with a current ratio of 5.152 and a quick ratio of 4.599.
Recent Earnings
Prenetics Global reported revenue of $120.07 million, showing a growth rate of 1.077. However, the company is currently not profitable, with a net margin of -41.99% and a return on equity of -40.77%. The next earnings report is scheduled for August 10, 2026.
Insider Buying and Selling at Prenetics Global Limited
Insider activity has been notable at Prenetics Global. On June 15, 2026, insider David Vanderveen bought 6,944 shares and sold 8,681 shares. Cheng Yin Pan also made transactions on the same day, buying and selling 15,873 shares. Earlier, on May 26, 2026, Pan purchased 6,406 shares. Chief Financial Officer Lo Hoi Chun acquired 91,629 shares on May 19, 2026.
Analysts Set New Price Targets
On June 16, 2026, Benchmark reiterated its buy rating with a $30 price target. Lake Street previously initiated coverage with a buy rating and a $29 target on March 16, 2026. The consensus among analysts is a strong buy, with an average price target of $31.25 based on four analyst opinions.
About Prenetics Global Limited
Prenetics Global Limited is a healthcare company based in Quarry Bay, Hong Kong. It focuses on consumer health sciences, developing science-backed products under the IM8 brand. The company also operates CircleDNA, a consumer genetic testing service offering personalized health reports. Founded in 2014, Prenetics aims to advance human health and longevity.
Bottom Line
Benchmark's reiterated buy rating highlights continued confidence in Prenetics Global's potential. Investors follow these analyst ratings closely as they provide insights into the company's future prospects. It's important to remember that such ratings are based on past performance and may not reflect current conditions.
Get Prenetics Global Limited alerts
New 13F filings, insider trades, and analyst moves on $PRE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.